Medindia
Medindia LOGIN REGISTER
Advertisement

Oramed Pharmaceuticals to Hold Conference Call on August 6 to Present Results of Phase 2A Oral Insulin Capsule Clinical Trials

Friday, August 1, 2008 General News
Advertisement
JERUSALEM, July 31 Oramed Pharmaceuticals, Inc.(OTCBB: ORMP) (http://www.oramed.com), a developer of oral delivery systems,announced today that it will hold a conference call on August 6, 2008 at10:30 AM EDT to present the results of its Phase 2A clinical trials of itsflagship product, ORMD 0801, an oral insulin capsule.
Advertisement

Oramed's Phase 2A trial is focused on assessing the safety and efficacyof ORMD 0801. This study is a continuation of the successfully completedPhase 1 studies in Israel.
Advertisement

Oramed Pharmaceuticals is a technology pioneer in the field of oraldelivery solutions for drugs and vaccines presently delivered via injection.Oramed is seeking to revolutionize the treatment of diabetes through itspatented flagship product, an orally ingestible insulin capsule currently inphase 2 clinical trials. Established in 2006, Oramed's technology is based onover 25 years of research by top research scientists at Jerusalem's HadassahMedical Center. The Company's corporate and R&D headquarters are based inJerusalem.

For more information, please visit http://www.oramed.com

Forward-looking statements

Some of the statements contained in this press release areforward-looking statements which involve known and unknown risks,uncertainties and other factors which may cause the actual results,performance or achievements of the company, or industry results, to bematerially different from any future results, performance or achievementsexpressed or implied by such forward looking statements, including the risksand uncertainties related to the progress, timing, cost, and results ofclinical trials and product development programs; difficulties or delays inobtaining regulatory approval for our product candidates; competition fromother pharmaceutical or biotechnology companies; and the company's ability toobtain additional funding required to conduct its research, development andcommercialization activities. Please refer to the company's filings with theSecurities and Exchange Commission for a comprehensive list of risk factorsthat could cause actual results, performance or achievements of the companyto differ materially from those expressed or implied in such forward lookingstatements. The company undertakes no obligation to update or revise anyforward-looking statements.Interested parties should dial: In the United States: +1-888-668-9141 All other locations: +972-3-918-0691 About Oramed Pharmaceuticals

SOURCE Oramed Pharmaceuticals Inc.
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close